/PRNewswire/ The global protein therapeutics market size is estimated to grow by USD 172.8 billion from 2024-2028, according to Technavio. The market is.
In an indication with few treatment options for patients who are running out of time, Replimune Group Inc. revealed positive top-line results of its lead candidate, RP-1 (vusolimogene oderparepvec), in anti-PD-1-failed melanoma. Data from the phase I/II Ignyte study of RP-1 plus Opdivo (nivolumab, Bristol Myers Squibb Co.) showed the treatment hit the primary endpoint with a 12-month overall response rate of 33.6% and a median duration of response of more than 35 months.
/PRNewswire/ The global gonorrhea therapeutics market size is estimated to grow by USD 541.5 billion from 2024-2028, according to Technavio. The market is.
See five large-cap dividend-paying companies trading at a significant discount to their historical norms. Click for our full monthly update of dividend picks.
Why Is Bristol Myers Squibb Stock Trading Higher On Friday? biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.